NEW YORK (GenomeWeb) – 23andMe has raised $79.1 million of a targeted $150 million in a private financing, according to a document filed with the US Securities and Exchange Commission.

In a filing with the SEC on July 2, 23andMe said it is seeking to raise $150 million through the sale of Series E Preferred Stock. It said that it made the first sale of stock in the round on June 18.

The firm said that 15 investors have participated in the round so far, but it did not disclose the names of those investors.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.